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When will we get a vaccine? That’s the
question Americans have been asking
since the novel coronavirus shut down
much of the country in March. Dr.
Anthony Fauci says it could happen this
year. Others think it will take a lot longer.
The HPV vaccine took fifteen years to
develop. The chickenpox vaccine took
twenty-eight. No widely effective vaccine
has ever been developed for many life-
threatening viruses, including
cytomegalovirus and HIV.
One potential way to speed up the
development of a vaccine for Covid-19 is a “challenge study,” in which researchers give
healthy subjects a prospective vaccine and then infect them with the coronavirus. In
conventional trials researchers typically give subjects either a test vaccine or a placebo and
follow them over time in their ordinary living conditions to see if the vaccine is effective.
But there’s no need to wait for a naturally occurring infection in a challenge study, which
allows it to be shorter and to require far fewer subjects. Yet such a study would also require
deliberately giving those subjects a potentially deadly illness for which there is no good
treatment, and for some observers, that’s a deal-breaker. A joint statement by the AIDS
Vaccine Advocacy Coalition and the Treatment Action Group says, “Until there is an
approved treatment, a challenge trial with a potentially fatal and as-yet untreatable
pathogen is unacceptable.”
A
Nonetheless, the drumbeat for Covid-19 challenge studies is growing louder, and some of
the most energetic drummers are bioethicists. Nir Eyal, a bioethicist at Rutgers, was one of
the first to call for them.  His proposal, cowritten with the epidemiologists Marc Lipsitch
of Harvard and Peter Smith of the London School of Hygiene and Tropical Medicine,
appeared online in late March. Challenge studies have also been endorsed by the NYU
bioethicist Arthur Caplan and the vaccinologist Stanley Plotkin.  Julian Savulescu and
Dominic Wilkinson, bioethicist-physicians at Oxford, have raised the moral stakes even
higher by proposing not just that researchers conduct Covid-19 challenge studies but that
the first human subjects could be elderly nursing home patients. “Their motives might be
purely altruistic,” Savulescu and Wilkinson wrote. “Or they may be fatalistic or wish to
die, or at any rate not care if they die sooner rather than later.”
The utilitarian argument for challenge studies is straightforward: calculate the number of
lives risked and compare it to the potential number of lives saved. Backers of challenge
studies point to a study (based on data from China) that estimates the risk of death from
Covid-19 for a healthy adult between the ages of twenty and twenty-nine at 0.03 percent.
And if subjects are recruited from hot spots where the risk of getting Covid-19 is very high
anyway, they argue, infecting them deliberately wouldn’t put them at much greater risk. At
least in a challenge study their medical condition would be closely monitored.
Challenge studies are troubling, of course, because many of us recoil at the thought of
infecting healthy human subjects with a pathogen. But such studies are not unusual. Nor
are they limited to the annals of past research abuses such as the Guatemala syphilis study
in the late 1940s, in which US Public Health Service workers gave syphilis and gonorrhea
to Guatemalan prisoners, soldiers, prostitutes, and psychiatric patients.  Not only have
infectious disease researchers in the modern era intentionally infected people with
pathogens ranging from influenza to malaria and cholera, but they have done it with the
approval of institutional review boards charged with protecting human subjects. Defenders
of challenge studies argue that there is nothing wrong with infecting subjects as long as
they have consented, the risks are minimized, and the studies are held to the same
established ethical standards as others are.
Many people are convinced that Covid-19 challenge studies should proceed. Thirty-five
members of the US House of Representatives have called for them. The World Health
Organization has not explicitly endorsed challenge studies, but it has published guidelines
for how they might be ethically conducted. Among the strategies the WHO recommends to
minimize risk to the initial subjects is to expose them to the virus “one by one, with
meticulous titration of viral dose.” Some scientists worry that a small study may not reveal
all the potential side effects of a vaccine, and that the results of a study on young healthy
people may not be relevant to older, less healthy patients. Nevertheless, a website for a







Auseful comparison is Phase I drug trials, which are usually conducted to determine if
experimental drugs are safe. As in challenge studies, researchers in Phase I trials
intentionally expose their subjects to potentially serious risks not in exchange for any
potential benefit to the subjects themselves but rather for the advancement of scientific
knowledge. Research sponsors typically pay subjects between $200 and $250 a day to
check into a locked research unit for several weeks while they are given an experimental
drug. Researchers usually monitor their blood, urine, and vital signs, and some studies
require invasive procedures such as lumbar punctures, biopsies, or endoscopies.
Because Phase I trials are such a routine part of drug development, bioethicists and social
scientists have subjected them to far more scrutiny than challenge studies. In Adverse
Events, the sociologist Jill Fisher has provided the most thorough examination yet.  What
can we learn from the way these trials are done?
Until the late 1970s most Phase I trials were done on prisoners.  Today they are done
mainly on poor people. A subject Fisher calls “Bob” was unemployed and on probation in
St. Louis when he began doing paid studies at Washington University. They didn’t pay
much, and some of them were grueling. One required him to ride a stationary bike with an
endoscopy tube down his throat. When his probation ended, Bob began traveling around
the country doing better-paid studies and competing in poker tournaments. By the time he
spoke to Fisher he had done drug studies in seventeen different states. “That’s my golden
vein,” he said, pointing to a scarred hole on his inner elbow where his blood had been
drawn. “You can see I got, you know, a cavern there. Been stuck many times.”
Like prisons, poultry processing plants, and funeral homes, Phase I trial sites occupy a
segment of the American economy that is not so much hidden as overlooked. If the world
that Fisher reveals in Adverse Events is unsettling, it is mainly because of the routinized,
factory-like conditions under which Phase I trials are conducted. The effect is a little like
that of Titicut Follies, Frederick Wiseman’s 1967 documentary about the Bridgewater State
Hospital for the criminally insane. What stands out is not the casual cruelty (although it is
occasionally evident) but the institutionalized indifference to the humanity of vulnerable
people.
Fisher did fieldwork in six trial sites across the country. One was an academic site in a
hospital, one was associated with a pharmaceutical company, four were commercial sites
(two of which were independent and two affiliated with contract research organizations).
The pharmaceutical company site was a state-of-the-art unit, but conditions at some of the
commercial sites were grim. One was located in a former manufacturing facility, another in
a converted warehouse. The largest was capable of housing three hundred subjects and
included a vast space with over eighty beds lined up in rows. On Fisher’s first visit to the
site, these beds were occupied by healthy subjects lying on their backs with their arms at




Several sites were located miles away from any hospital emergency room. Fisher compares
them to “overcrowded prisons.” Yet many subjects had seen far worse. “We had dogs—
bedbug sniffing dogs—come in because there were bedbugs in the facility,” one subject
said. “Air conditioners were broken. The beds would stink…. It was horrible.”
Some of us may imagine that research subjects take part in studies for humanitarian
reasons. But in Phase I trial sites this is rare. “I wanted to make some money,” one subject
told Fisher. “It’s definitely not because I want to save the world. Let’s get that on the
record right now.” While some of those Fisher talked to have enrolled in the occasional
trial to make extra cash—to finance a vacation or an expensive engagement ring—most are
serial research subjects with few alternatives. “What are we gonna do?” said a Native
American man in his late twenties. “If I don’t pay my parole, I’m gonna go back to
prison.” A young Hispanic woman whose husband had also done studies for money told
Fisher, “Because we are not here legally, we don’t have another option left.”
Many of the subjects felt so ashamed of their participation that they hid it from their
friends. “Once they call you a lab rat, you’re done,” a subject said. “You’re like a roasted
duck. It’s over.” The shame frequently came on top of other stigmatizing conditions:
unemployment, poverty, a criminal record, lack of immigration papers.
Of the 235 research subjects Fisher interviewed, over 60 percent were minorities and 35
percent were African-American. Over a third of African-American subjects had done more
than ten studies, and six African-American men had done over fifty. Fisher didn’t ask
subjects specifically about their income or health insurance, but the answers would likely
have been depressing. A survey of a Pfizer trial site in Connecticut found that only 12.5
percent of the subjects had full-time employment.  Nearly half had household incomes
below $25,000 a year, and over 38 percent had no health insurance. These figures raise
troubling issues. Even if the drugs in Phase I trials are eventually approved, many of the
subjects who have tested them may not be able to afford them if they get sick.
f all goes well in a study (as it generally does), subjects experience no side effects or only
minor ones, such as nausea, headaches, or a rash. Yet many of Fisher’s subjects had
disturbing stories. One told her about a study in which the majority of participants
experienced sleep paralysis, a frightening state of being conscious but unable to move or
speak, which can include vivid hallucinations. A subject who tested a drug for ADHD
described the effects as something out of a horror movie. “I thought that I was going
crazy,” she said. Another took part in an antibiotic study in which the subjects lost control
of their bodily functions. “So, at the same time we were throwing up, everything else was
releasing,” she said. “It was like a scene out of Poltergeist.”
Some of the subjects Fisher interviewed avoided Phase 1 vaccine trials, worrying that they
were too dangerous or that long-term side effects would disqualify them from doing more
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trials. And indeed some Phase 1 vaccine studies have had serious problems. In 2004 an
Alabama physician paid twenty-one clients of a homeless center to test an experimental
smallpox vaccine. Two had to be hospitalized and a third contracted pericarditis.
Only rarely do subjects in Phase I trials die. Traci Johnson, a nineteen-year-old student,
committed suicide in 2004 during an antidepressant study at an Eli Lilly facility in
Indianapolis. A mentally ill veteran, Walter Jorden, died of a heart attack at a New Jersey
trial site in 2007 while testing an antipsychotic medication. In 2016 a previously healthy
volunteer died and several others were severely injured while testing an experimental drug
at a Biotrial facility in France. In 2006 six healthy subjects at a trial site at Northwick Park
Hospital in the United Kingdom came very close to death after an experimental
monoclonal antibody sent them into multisystem organ failure.
Most of the subjects Fisher interviewed had been desensitized to the risks they were
taking, mainly out of sheer repetition. “The reason why I don’t too much think about the
risk [is] because I’ve done it so many times,” a Pakistani immigrant said. “If something
was supposed to happen to me, it would have done happened already.” Some subjects even
claimed that the studies were good for them. “I know what my labs look like, and I’m
more healthier now doing clinical trials than I’ve ever been in my life,” said one subject.
Staff members were skeptical. With near unanimity they told Fisher that the informed
consent process for the trials had serious problems. Fisher interviewed one subject who
had turned down an infection challenge study after reading in the consent form that
participants had to drink feces-tainted water. An acquaintance who had consented to the
study didn’t understand what “feces” or “excrement” meant. “He was like, ‘What does that
[word] mean?’” the subject said. “I had to be like, ‘Look, dude, like they want you to drink
dookie in a cup of water!’”
One of the most revealing stories in Adverse Events took place at the gleaming
pharmaceutical industry clinic. An Alzheimer’s study required subjects to undergo a
procedure that many of them dreaded like no other: a lumbar puncture, or “spinal tap.”
While lumbar punctures are routine procedures in skilled hands, they can sometimes cause
bleeding, infections, piercing headaches, and, in rare cases, brain herniation. Two
anesthesiologists had been hired to place a catheter in the spines of subjects so their
cerebrospinal fluid could be collected over a period of several hours.
A nurse brought Fisher into the research subject’s room. Five staff members were there, all
white. The subject was black. He sat hunched and silent on the bed. (Fisher calls him
“Devon.”) Without speaking to Devon, a white anesthesiologist injected his back with
lidocaine and threaded a hollow needle through his vertebrae. But the anesthesiologist
hired to place the catheter had not arrived, so everyone waited. More than twenty minutes
after the appointed starting time, the second anesthesiologist finally turned up.
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Without a word to Devon, the second anesthesiologist threaded a catheter into the hollow
lumbar needle and the cerebrospinal fluid began to flow. But the catheter was not
connected to a collection container, so the fluid just spilled out. Finally a staff member
noticed and connected it to a specimen tube.
Devon endured the procedure unflinchingly, yet it never even occurred to the researchers
to speak to him. They might as well have done the lumbar puncture on a plastic dummy.
The routine use of Phase I trial subjects for purely instrumental purposes is one reason
Fisher compares them to “model organisms” such as fruit flies or guinea pigs: “Like a
laboratory animal in an experiment, Devon was a mere object of the procedure, providing
the biological material that needed to be sampled without regard to informing him what
was happening to his body.”
n 1969 the philosopher Hans Jonas tried to pinpoint exactly what is morally disturbing
about the use of human subjects in medical research. “What is wrong with making a person
an experimental subject is not so much that we make him thereby a means,” Jonas wrote,
“as that we make him a thing—a passive thing merely to be acted on.”  Jonas thought the
way to right this fundamental wrong was to bolster the subjects’ agency. They should not
merely consent to an experiment, Jonas argued, but embrace its purpose as their own.
The things that disturbed Jonas most about medical research have become a routine part of
Phase I drug trials. The research subjects are treated as instruments for purposes they don’t
identify with, they are drawn from the most vulnerable segments of American society, and
the research is often conducted under grim, dehumanizing conditions. Yet this doesn’t have
to be the case for Covid-19 vaccine challenge studies. The pandemic has created a sense of
urgency and shared purpose that is rare for medical research. Many idealistic young people
not only embrace the purpose of Covid-19 vaccine studies but seem willing to risk their
health for the common good. The question is how to make those studies safe and fair.
Imagine volunteering for a challenge study and the very worst happens: you die or are
permanently disabled. What conditions would need to be in place for you or your family to
conclude that you had been treated fairly? It goes without saying that you should have the
rights elaborated in the Declaration of Helsinki, such as informed consent and the
minimization of risk. But you might also ask that the study sponsor pay for your medical
bills if you become ill. You might believe you deserve financial support if you are injured
so badly that you could never hold a job again. You might ask for a promise that the
vaccine developed from the study would be priced fairly and made available to everyone
who needs it. At a minimum, you might want a guarantee that the data from the study




Unfortunately, research subjects in the United States are not guaranteed any of these
things. Research sponsors have no legal obligation to pay for the medical care of subjects
who have been injured or sickened in a study.  This sets the US apart from every other
developed country. According to The New England Journal of Medicine, a 2005 report for
the Department of Health and Human Services found that only 16 percent of academic
medical centers in the US made it a policy to pay for the care of injured subjects.  A 2012
survey found that over half of research institutions offered no compensation for research-
related injuries, and only 1.2 percent offered any compensation beyond payment for
immediate medical care.  The US does maintain a National Vaccine Injury Compensation
Program, but it excludes payment for experimental vaccines.
Nor does the US have a stellar record when it comes to paying restitution to mistreated
research subjects. This includes subjects injured in challenge studies. President Obama
apologized for the Guatemala syphilis study in 2011, but the US government has refused to
pay any compensation to the victims or their family members. Between 1951 and 1974 Dr.
Albert Kligman, a dermatologist at the University of Pennsylvania, deliberately infected
inmates at Holmesburg Prison with herpes simplex, herpes zoster, vaccinia,
papillomaviruses, staph aureus, and ringworm. Not only has the University of
Pennsylvania never paid any compensation to the victims for their suffering, it honored
Kligman with two endowed professorships and a lectureship in his name.
It would also be a mistake to assume that drugmakers will be honest and open about their
research results. It is not just that many have repeatedly failed to publish unfavorable data.
As the former editor of The BMJ has written, many have simply designed their research
studies to produce the results they want. Medical journal editors have been raising the
alarm about this for over fifteen years now.  Between 1991 and 2010, according to Public
Citizen, the pharmaceutical industry was the leading defrauder of the federal government,
as measured by penalties paid for violating the False Claims Act. The worst scandals have
involved prescription drugs such as Paxil and Bextra, but many of the companies accused
of burying or manipulating research results are now racing to produce a Covid-19 vaccine.
he barriers to creating ethical Covid-19 vaccine challenge studies are not
insurmountable. Some problems could be solved easily. For instance, research sponsors
could eliminate many of the more exploitative elements of Phase I trials simply by limiting
Covid-19 vaccine challenge studies to unpaid volunteers. Other problems, such as the issue
of compensation for research-related injuries, would require major legislative or policy
changes. Yet the bioethicists calling for Covid-19 challenge studies have not mentioned
these issues, which are so deeply entrenched in the system that they are viewed as the

















The World Health Organization lists a number of potential risks for challenge studies,
among them a loss of public trust in vaccines and medical research if a research subject
were to die. That risk is not unique to challenge studies, of course. But it would probably
be far worse if the subject had been intentionally infected. While defenders of challenge
studies argue that there is nothing intrinsically wrong with intentionally exposing willing
subjects to harm, the public hasn’t always seen things that way. For instance, until the early
2000s many psychiatric researchers conducted psychosis challenge studies on mentally ill
patients. They typically used ketamine, amphetamines, or other drugs to make patients
severely psychotic. Many psychiatrists saw no ethical problem with this, since mentally ill
patients would probably experience psychotic episodes in the course of their illness
anyway. It was only after patients and their advocates subjected the challenge studies to
blistering criticism in the press that they were finally stopped.
The Covid-19 crisis has presented the medical research community with a rare opportunity.
At no time in recent memory has the importance of research subjects been so evident. If a
nonprofit organization can sign up over 26,000 volunteers for challenge studies in a matter
of months, it should be possible to reform the oversight system so that research subjects
are treated fairly. But those reforms would entail structural changes that unfortunately
neither the research community nor those of us who benefit from medical research have
shown any interest in making.
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